Methyl prednisolonate (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04450030 (ClinicalTrials.gov) | August 1, 2018 | 24/6/2020 | Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis | Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis - Assessment of Mechanism of Action | Multiple Sclerosis, Relapsing-Remitting | Drug: Methyl Prednisolonate;Procedure: Immunoadsorption | University Hospital Muenster | NULL | Active, not recruiting | 18 Years | 65 Years | All | 204 | Germany |